Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSHUA A WHATLEY

Allopathic & Osteopathic Physicians Family Medicine

NPI
1386961787
CMS profile
335838
Location
LAKE CHARLES, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$1,613.01

107 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,613.01 107

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 3; records 1–50 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSHUA A WHATLEY

NPI 1386961787 · CMS profile ID 335838

Allopathic & Osteopathic Physicians / Family Medicine

LAKE CHARLES, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 3; records 1–50 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1386961787?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSHUA A WHATLEY, NPI 1386961787, CMS profile ID 335838. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1386961787?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). JOSHUA A WHATLEY, NPI 1386961787, CMS profile ID 335838. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1386961787?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
JOSHUA A WHATLEY, NPI 1386961787, CMS profile ID 335838, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 3; records 1–50 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1386961787?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

107 matching records · $1,613.01 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 107 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 107.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Allergan, Inc. $17.2612/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723706609 CMS
GlaxoSmithKline, LLC. $12.5612/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738740549 CMS
Novo Nordisk Inc $17.2112/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745034355 CMS
Janssen Pharmaceuticals, Inc $16.6012/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719230159 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.5112/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747321875 CMS
Allergan, Inc. $5.2912/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723706607 CMS
AstraZeneca Pharmaceuticals LP $11.5612/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736337231 CMS
Merck Sharp & Dohme Corporation $15.9711/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747811553 CMS
Allergan, Inc. $12.7211/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723706605 CMS
Allergan, Inc. $4.2811/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723706603 CMS
Novo Nordisk Inc $13.1611/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745000645 CMS
Amgen Inc. $17.0511/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741404945 CMS
Teva Pharmaceuticals USA, Inc. $11.4811/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749556887 CMS
GlaxoSmithKline, LLC. $13.0111/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738725157 CMS
Lilly USA, LLC $15.5011/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728511103 CMS
Allergan, Inc. $5.7311/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723706601 CMS
Amarin Pharma Inc. $12.2211/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739942903 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.7911/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747321873 CMS
AstraZeneca Pharmaceuticals LP $13.6510/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736242691 CMS
Novo Nordisk Inc $12.3910/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744929937 CMS
Novo Nordisk Inc $13.5910/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744952397 CMS
Allergan, Inc. $2.1110/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723706599 CMS
Novo Nordisk Inc $13.7710/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744917403 CMS
AstraZeneca Pharmaceuticals LP $13.0610/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736169747 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.6409/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720766513 CMS
Lilly USA, LLC $16.1009/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728500979 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.3709/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747321871 CMS
Novo Nordisk Inc $9.5309/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744906877 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.4509/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737637117 CMS
Amgen Inc. $13.9509/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741158731 CMS
Allergan, Inc. $14.1008/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723706597 CMS
Novo Nordisk Inc $12.1708/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744848927 CMS
Amgen Inc. $23.5708/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741158703 CMS
Lilly USA, LLC $14.5208/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728500981 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.7308/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747321869 CMS
Novo Nordisk Inc $18.7908/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744977141 CMS
SANOFI-AVENTIS U.S. LLC $12.3508/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744269623 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.0908/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720766517 CMS
GlaxoSmithKline, LLC. $18.3908/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738470387 CMS
PFIZER INC. $17.6508/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743746877 CMS
Novo Nordisk Inc $20.3007/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744807075 CMS
Novo Nordisk Inc $13.1507/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744807509 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.5407/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747321867 CMS
Amarin Pharma Inc. $24.4107/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739924173 CMS
Novo Nordisk Inc $13.7207/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744807519 CMS
Lilly USA, LLC $14.6707/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728504283 CMS
Eisai Inc. $15.2907/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751213161 CMS
Amgen Inc. $18.4107/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741158709 CMS
AbbVie Inc. $13.5507/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722180565 CMS
Teva Pharmaceuticals USA, Inc. $14.2807/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749477411 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,052.70 165
PY2020 $1,613.01 107
PY2021 $3,626.66 165
PY2022 $2,624.95 158
PY2023 $2,196.01 133
PY2024 $2,213.51 134
PY2025 $2,340.57 130

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $163.24 1
PY2023 Principal investigator $22,600.32 6
PY2022 Principal investigator $180,941.31 164
PY2021 Principal investigator $125,292.52 151
PY2020 Principal investigator $20,750.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

164 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $317.74 12/31/2022 Non-covered Recipient Entity
CENTEX STUDIES, INC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 914601067
Principal investigator 1 Janssen Pharmaceuticals, Inc $1,694.00 12/27/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885221092
Principal investigator 1 Janssen Pharmaceuticals, Inc $507.00 12/16/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885221097
Principal investigator 1 ABBVIE INC. $2,200.00 11/03/2022 Non-covered Recipient Entity
C-1 HEADLANDS LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889818139
Principal investigator 1 Janssen Pharmaceuticals, Inc $7,576.00 10/26/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885221105
Principal investigator 1 ABBVIE INC. $1,295.63 10/14/2022 Non-covered Recipient Entity
C-1 HEADLANDS LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889816573
Principal investigator 1 Janssen Pharmaceuticals, Inc $3,965.00 10/07/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885221099
Principal investigator 1 Janssen Pharmaceuticals, Inc $170.00 09/23/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885221083
Principal investigator 1 Janssen Pharmaceuticals, Inc $5,580.00 09/14/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885221081
Principal investigator 1 Janssen Pharmaceuticals, Inc $6,300.00 09/14/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885221087
Principal investigator 1 Janssen Pharmaceuticals, Inc $670.00 09/02/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885221075
Principal investigator 1 Janssen Pharmaceuticals, Inc $504.00 08/24/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885221071
Principal investigator 1 ABBVIE INC. $8.00 08/12/2022 Non-covered Recipient Entity
C-1 HEADLANDS LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889806139
Principal investigator 1 ABBVIE INC. $565.38 08/08/2022 Non-covered Recipient Entity
C-1 HEADLANDS LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889803855
Principal investigator 1 ABBVIE INC. $1,434.33 08/03/2022 Non-covered Recipient Entity
C-1 HEADLANDS LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889803045
Principal investigator 1 Janssen Pharmaceuticals, Inc $1,554.00 07/22/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885221067
Principal investigator 1 ABBVIE INC. $701.04 07/19/2022 Non-covered Recipient Entity
C-1 HEADLANDS LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889801593
Principal investigator 1 ABBVIE INC. $1,015.38 07/14/2022 Non-covered Recipient Entity
C-1 HEADLANDS LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889800615
Principal investigator 1 Janssen Pharmaceuticals, Inc $1,395.00 07/13/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885221063
Principal investigator 1 Janssen Pharmaceuticals, Inc $630.00 07/08/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885221059
Principal investigator 1 Janssen Pharmaceuticals, Inc $279.00 07/05/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885221055
Principal investigator 1 Janssen Pharmaceuticals, Inc $340.00 06/20/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885221051
Principal investigator 1 Alnylam Pharmaceuticals Inc. $832.00 06/17/2022 Non-covered Recipient Entity
C-1 Headlands, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910108707
Principal investigator 1 Janssen Pharmaceuticals, Inc $1,392.00 06/15/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885221049
Principal investigator 1 ABBVIE INC. $100.00 06/14/2022 Non-covered Recipient Entity
C-1 HEADLANDS LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889795281
Principal investigator 1 ABBVIE INC. $71.12 06/14/2022 Non-covered Recipient Entity
C-1 HEADLANDS LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889795285
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 06/10/2022 Non-covered Recipient Entity
C-1 Headlands, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910108711
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 06/10/2022 Non-covered Recipient Entity
C-1 Headlands, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910108713
Principal investigator 1 ABBVIE INC. $1,025.00 06/02/2022 Non-covered Recipient Entity
C-1 HEADLANDS LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889793519
Principal investigator 1 Janssen Pharmaceuticals, Inc $378.00 06/01/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885221043
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089863
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089971
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089979
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089987
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089996
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910090005
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910090017
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910090025
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910090035
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910090045
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910090055
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910090063
Principal investigator 1 Alnylam Pharmaceuticals Inc. $420.00 05/25/2022 Non-covered Recipient Entity
C-1 Headlands, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910108703
Principal investigator 1 Alnylam Pharmaceuticals Inc. $126.00 05/25/2022 Non-covered Recipient Entity
C-1 Headlands, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910108709
Principal investigator 1 Alnylam Pharmaceuticals Inc. $168.00 05/25/2022 Non-covered Recipient Entity
C-1 Headlands, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910108715
Principal investigator 1 Janssen Pharmaceuticals, Inc $4,220.00 05/20/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885221041
Principal investigator 1 Janssen Pharmaceuticals, Inc $2,088.00 05/18/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885221035
Principal investigator 1 Janssen Pharmaceuticals, Inc $2,742.00 05/09/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885221031
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089783
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089791
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089801
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089809
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089819
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089829
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089837
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089845
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089853
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089873
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/29/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089881
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089889
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089897
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089907
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089915
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089925
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089935
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089943
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089951
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/29/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089961
Principal investigator 1 Janssen Pharmaceuticals, Inc $170.00 04/25/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885221027
Principal investigator 1 Janssen Pharmaceuticals, Inc $696.00 04/22/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885221023
Principal investigator 1 ABBVIE INC. $65.00 04/21/2022 Non-covered Recipient Entity
C-1 HEADLANDS LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889787945
Principal investigator 1 Janssen Pharmaceuticals, Inc $1,071.00 04/12/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885221020
Principal investigator 1 Janssen Pharmaceuticals, Inc $1,392.00 04/11/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885221017
Principal investigator 1 Janssen Pharmaceuticals, Inc $252.00 04/08/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885221013
Principal investigator 1 Alnylam Pharmaceuticals Inc. $168.00 04/06/2022 Non-covered Recipient Entity
C-1 Headlands, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910108705
Principal investigator 1 Janssen Pharmaceuticals, Inc $135.00 04/06/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885221009
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089239
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089247
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089257
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089265
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089273
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089283
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089291
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089301
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089307
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089315
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089325
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089335
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089345
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089353
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089361
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089369
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089379
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089389
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089399
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089409
Principal investigator 1 Janssen Pharmaceuticals, Inc $2,229.00 03/28/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885221005
Principal investigator 1 Janssen Pharmaceuticals, Inc $630.00 03/25/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885221001
Principal investigator 1 Janssen Pharmaceuticals, Inc $1,340.00 03/18/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885220997
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,011.51 03/11/2022 Non-covered Recipient Entity
CENTEX STUDIES, INC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 914602553
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,000.00 03/09/2022 Non-covered Recipient Entity
C-1 Headlands, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910108605
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,500.00 03/09/2022 Non-covered Recipient Entity
C-1 Headlands, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910108607
Principal investigator 1 Alnylam Pharmaceuticals Inc. $416.00 03/09/2022 Non-covered Recipient Entity
C-1 Headlands, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910108609
Principal investigator 1 Alnylam Pharmaceuticals Inc. $9,500.00 03/09/2022 Non-covered Recipient Entity
C-1 Headlands, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910108611
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,000.00 03/09/2022 Non-covered Recipient Entity
C-1 Headlands, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910108613
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,000.00 03/09/2022 Non-covered Recipient Entity
C-1 Headlands, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910108615
Principal investigator 1 Alnylam Pharmaceuticals Inc. $252.00 03/09/2022 Non-covered Recipient Entity
C-1 Headlands, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910108617
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 03/09/2022 Non-covered Recipient Entity
C-1 Headlands, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910108619
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,000.00 03/09/2022 Non-covered Recipient Entity
C-1 Headlands, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910108621
Principal investigator 1 ABBVIE INC. $8.00 03/03/2022 Non-covered Recipient Entity
C-1 HEADLANDS LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889779167
Principal investigator 1 ABBVIE INC. $16.90 03/03/2022 Non-covered Recipient Entity
C-1 HEADLANDS LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889779169
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $15,886.50 03/02/2022 Non-covered Recipient Entity
C1 Headlands LLC
POCC in NASH No dispute reported 06/30/2026 949201365
Principal investigator 1 Janssen Pharmaceuticals, Inc $775.00 03/02/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885220991
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089600
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089609
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089619
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089627
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089635
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089645
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089655
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089663
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089671
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089679
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089689
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089697
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089705
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089713
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089721
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089729
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089737
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089747
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089755
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089765
Principal investigator 1 ABBVIE INC. $16.90 02/17/2022 Non-covered Recipient Entity
C-1 HEADLANDS LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men (TRAVERSE) No dispute reported 06/30/2026 889778019
Principal investigator 1 ABBVIE INC. $71.12 02/17/2022 Non-covered Recipient Entity
C-1 HEADLANDS LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men (TRAVERSE) No dispute reported 06/30/2026 889778025
Principal investigator 1 ABBVIE INC. $485.00 02/16/2022 Non-covered Recipient Entity
C-1 HEADLANDS LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men (TRAVERSE) No dispute reported 06/30/2026 889777639
Principal investigator 1 ABBVIE INC. $1,548.36 02/16/2022 Non-covered Recipient Entity
C-1 HEADLANDS LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men (TRAVERSE) No dispute reported 06/30/2026 889777641
Principal investigator 1 Janssen Pharmaceuticals, Inc $49,759.00 02/16/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885220988
Principal investigator 1 ABBVIE INC. $4,558.48 02/03/2022 Non-covered Recipient Entity
C-1 HEADLANDS LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men (TRAVERSE) No dispute reported 06/30/2026 889775759
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089417
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089427
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089433
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089443
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089451
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089461
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089471
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089479
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089489
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089499
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 910089507
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089515
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089525
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089535
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089545
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089555
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089563
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089573
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089581
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2022 Non-covered Recipient Entity
Centex Studies Inc.
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 910089591
Principal investigator 1 Janssen Pharmaceuticals, Inc $450.00 01/26/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885220984
Principal investigator 1 Janssen Pharmaceuticals, Inc $2,940.00 01/21/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885220981
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,995.00 01/21/2022 Non-covered Recipient Entity
CENTEX STUDIES INC
AN OPEN-LABEL EXTENSION TRIAL OF THE PHASE III LIPID-LOWERING TRIALS TO ASSESS THE EFFECT OF LONG TERM DOSING OF INCLISIRAN GIVEN AS SUBCUTANEOUS INJECTIONS IN SUBJECTS WITH HIGH CARDIOVASCULAR RISK AND ELEVATED LDL-C No dispute reported 06/30/2026 909394527
Principal investigator 1 Janssen Pharmaceuticals, Inc $696.00 01/19/2022 Non-covered Recipient Entity
C-1 Headlands, Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885220975
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $808.92 01/01/2022 Non-covered Recipient Entity
Centex Studies
POCC in NASH No dispute reported 06/30/2026 946886535